Recently, a retrospective analysis was performed on 2276 patients with NSCLC who received different types of therapy, including PD-1/PD-L1 in beta-blockers, chemotherapy, and tyrosine kinase inhibitors. This evidence concerns the gene CD274 and non-small cell lung carcinoma.